Rallis India to sell its entire stake in Advinus to Eurofins Pharma
Jul. 21, 2017
Eurofins Pharma, known for its expertise in bioanalytical testing, will purchase Advinus’ 13.68 percent stake at Rs 9.47 per share, Rallis India said in an exchange filling.
Advinus is owned by Tata Sons, Tata Industries and Rallis India and a few individual shareholders. The transaction is expected to close in the “next several weeks”, Tata Sons said in a separate statement.
As part of deal, the drug discovery operations of the Tata Group-promoted company, which deals in research and development services, will be transferred to Impetis Biosciences. Rallis will buy 13.7 percent stake in Impetis for about Rs 3.5 crore, the exchange filing added.
"With access to Eurofins’ global network and technical competencies, Advinus will be able to rapidly expand its analytical portfolio and services to benefit all its existing and future clients,” KRS Jamwal, Chairman of Advinus and Executive Director of Tata Industries said.
As part of the deal, Rallis will be released of its Rs 45.60 crore gaurantee for Advinus’ borrowings.
Join Discussion
More from AgroNews
-
Higher tier testing would answer neonicotinoid pesticide question -
Top 20 Brazilian agrochem companies in 2017: Mergers will increase market concentration in the future -
Sichuan Lomon Bio Takes S-ABA and Gibberellin as Core Products to Build Full Range Product Line on Basis of Biotechnology -
AkzoNobel Specialty Chemicals rebrands as Nouryon
